Parkinson Platform Noord Nederland

Parkinson's disease is characterised by striatal dopamine depletion. The most effective treatment for the disease is oral levodopa (dopamine's lipophilic precursor) in combination with an aromatic l-amino acid decarboxylase inhibitor (to reduce the peripheral degradation of levodopa).1 However, long-term treatment with levodopa and decarboxylase inhibitor (hereafter referred to as levodopa therapy) is complicated by the development of motor fluctuations and dyskinesia.